NCI NCORP-designated LSU Health New Orleans and ConcertAI Advance Multi-Year Collaboration Addressing Diversity in Clinical Trials

Collaboration Utilizes RWD-enabled Capabilities Across Hospitals and Research Organizations to Transform the Elimination of Disparities

NEW ORLEANS and CAMBRIDGE, Mass., Sept. 27, 2022 /PRNewswire/ -- The National Cancer Institute Community Oncology Research Program (NCI NCORP)-designated Louisiana State University (LSU) Health New Orleans and ConcertAI, LLC (ConcertAI) announced a five-year partnership to improve the diversity of clinical trials and ensure broader clinical trial access throughout the Gulf South region.

The collaboration aligns to ConcertAI's ERACE program. ERACE (Engaging Research to Achieve Cancer Care Equality) furthers equitable access, care, and outcomes for all patients using Real-world Data (RWD) and advanced technologies.

"This is urgent and vital work that will form the foundations of true equity in healthcare," said Jeff Elton, PhD and CEO of ConcertAI. "LSU Health New Orleans and ConcertAI believe addressing disparities starts with a foundation of data and a diversity of clinical settings that explicitly assure the broadest representativeness and generalizability. This, combined with the latest real-world analytic and AI-enabled software assure insights progress to practice in weeks and months versus years."

"The collaboration will identify current cancer care disparities in Louisiana and how they can be addressed," said Augusto Ochoa, MD, and LSU Health New Orleans NCORP Principal Investigator. "Insights gleaned from the novel real-world data advanced by the partnership will lead to evidence-based strategies to reduce health inequities among populations with existing disparities, including the implementation of AI-based capabilities to improve patient screening, engagement and recruitment at clinical trial sites throughout the region."

The collaboration is in line with the vision of NCI NCORP leadership. A $5.6 million grant from the NCI helped LSU Health New Orleans establish a clinical trials network throughout the Gulf South region. The NCI then awarded LSU Health New Orleans a $13.6 million grant to expand the network, emphasizing minority and underserved patients.

Together with LSU's clinical trial sites and real-world data from ConcertAI's nationwide cancer care settings and "system of evidence," the collaboration will assess the impact of the Gulf South Minority Underserved NCORP program on minority enrollment in clinical trials, retention, and health outcomes. Joining the effort is LSU Health New Orleans' Louisiana Tumor Registry (LTR), one of 21 cancer registries comprising the NCI's Surveillance, Epidemiology, and End Results (SEER) program. Funded by the grants from the NCI and CDC, it collects complete, high-quality, and timely population-based data in Louisiana to support cancer research, control, and prevention.

"We are eager to participate in this partnership and continuing to reduce the state's cancer burden and disparities and improve the survival and quality of life for all cancer patients," said Xiaocheng Wu, MD, MPH, Director of the TR at LSU Health New Orleans School of Public Health

"Gaining insights from related clinical trials and EMR data from LSU Health New Orleans and the LTR is unique, so we're particularly excited about the important research questions we can answer with the combination of such data sources as they relate to improving diversity in clinical trials," said Sudip Bhandari, PhD, lead ConcertAI data scientist for the partnership.

Overseeing the overall vision and direction of the partnership are Warren A. Whyte, PhD, Vice President and ERACE lead for ConcertAI; and John H. Stewart, IV, MD, MBA, FACS, Director of the LSU Health New Orleans-LCMC Cancer Center.

"This partnership will integrate disease-specific research and care delivery into a comprehensive patient-oriented approach to benefit patients of Louisiana, including those currently underserved in accessing leading-edge cancer care," said Whyte.

"We are thrilled to work with ConcertAI in furthering our efforts to improve quality and expanding access for the people we serve throughout the state," said Dr. Stewart. "This collaboration will set the stage for us to more fully define factors that identify risks and prognosis and patient characteristics that will enhance clinical trial enrollment."

ConcertAI is the global leader in life sciences and healthcare enterprise AI and RWD SaaS solutions. Our mission is to broadly advance the goals of precision medicine, accelerate delivery of innovative new therapies, generate evidence in support of regulatory and reimbursement decisions, support provider clinical decisions, and improve clinical outcomes for patients. We work in partnership with the leading biomedical innovators, health care providers, and medical societies. For more information, visit http://www.concertai.com.

LSU Health Sciences Center New Orleans (LSU Health New Orleans) educates Louisiana's health care professionals. The state's health sciences university leader, LSU Health New Orleans includes a School of Medicine with campuses in Baton Rouge and Lafayette, the state's only School of Dentistry, Louisiana's only public School of Public Health, and Schools of Allied Health Professions, Nursing, and Graduate Studies. LSU Health New Orleans faculty take care of patients in public and private hospitals and clinics throughout the region. In the vanguard of biosciences research, the LSU Health New Orleans research enterprise generates jobs and enormous annual economic impact. LSU Health New Orleans faculty have made lifesaving discoveries and continue to work to prevent, advance treatment or cure disease. To learn more, visit http://www.lsuhsc.edu, http://www.twitter.com/LSUHealthNO, or http://www.facebook.com/LSUHSC.

Chris Gale, [email protected]

SOURCE ConcertAI